Choose Chicago Announces Tourism & Hospitality Forward To Responsibly Welcome Visitors Back To Chicago

CHICAGO, May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — At the Choose Chicago Annual Meeting today, the organization announced <a target="_blank"…

CHICAGO, May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — At the Choose Chicago Annual Meeting today, the organization announced Tourism & Hospitality Forward, a new initiative to accelerate and spur Chicago’s tourism industry post-coronavirus and help expedite the City’s economic recovery. To date, a coalition of more than 250 local tourism, hospitality, meeting and event-related organizations and businesses have signed on to the pledge promising alignment, collaboration and socially responsible tourism and hospitality that will instill confidence in residents and visitors as they return to Chicago.

«This current crisis has been simply devastating to so many, including the tourism and hospitality industry, and we recognize that these unprecedented challenges require unprecedented and swift actions in order to restore this economic driver for the City,» said Glenn Eden, Chair of the Choose Chicago Board of Directors. «Our first priority is to promote socially responsible tourism. We will demonstrate to our guests that through the operational changes and precautions taken, it is safe to enjoy Chicago again.»

Chicago’s tourism, hospitality, meetings, and events industries were amongst the hardest hit by the coronavirus disease 2019 (COVID-19) pandemic. As the City transitions through a phased reopening, this alliance of industry partners will work together to establish best practices and safety measures for the health and safety of residents and visitors alike when cultural institutions, hotels, attractions and restaurants return to regular business and welcome guests.

«I applaud Choose Chicago’s commitment to developing safe, collaborative solutions to the profound impact COVID-19 has had on our city’s vital tourism and hospitality industry,» said Mayor Lori E. Lightfoot. «Despite the challenges we face, the strength of our recovery is being built on forward-looking partnerships like these which are mutually supportive and rooted in the data of this disease, allowing us to build and grow more resilient, inclusive, and powerful than we’ve ever been.»

There are four components to the pledge:

  • SOCIALLY RESPONSIBLE PLANNING: We will put the safety of our patrons and employees first by adhering to public health guidance and direction and become leaders in socially responsible tourism and hospitality.
  • DEDICATED AND STRATEGIC ENGAGEMENT: We will recognize the importance of taking a strategic and collaborative approach by dedicating the time to align across sectors and develop the phased plans we need to thrive in this challenging environment.
  • AUTHENTIC AND INCLUSIVE EXCELLENCE: We will work together to spur the traffic of Chicago visitors and guests by enhancing our efforts to create unique ways to leverage all of the city’s dynamic neighborhoods and authentic assets.
  • UNPARALLELED CHICAGO ADVOCACY: We advocate for all that Chicago has to offer by cross-promoting offerings and collaborating on shared offers to create a mutually beneficial environment for the industry and ultimately a stronger economy for the city.

Additionally, Tourism & Hospitality Forward announced an outreach and engagement framework that participants can leverage to bring visitors back to Chicago when the time is right. The framework includes:

  • Promoting Chicago’s reopening in a calibrated manner with programs and promotions, such as staycations, designed to engage local audiences.
  • Launching seasonal initiatives to bring leisure travelers to Chicago with an emphasis on neighboring states.
  • Reinforcing that Chicago will continue to be the best place to do business as the City competes for meetings and events.
  • Maximizing all Chicago has to offer through a unifying marketing campaign.

Planning has been underway with several working groups aligned by sector, including accommodations, museums and attractions, arts & culture, festivals, and special events including sports and a dedicated focus on unique and diverse neighborhoods.  

«These groups initially began meeting to focus on initial and almost immediate reopening strategies,» said Eden. «They have now evolved and have been rolled up to collaborate with and support Mayor Lightfoot’s longer-term Reopening and Recovery Task Force, including marketing and economic development for the City as a whole.»

«The traditional visitor and convention delegate will remain our ultimate goal in the recovery process,» said David Whitaker, President & CEO of Choose Chicago. «In the early phases of reopening we are going to have to focus and rely on our local residents, nearby suburban and regional visitors and the drive market as a whole. While they will be the first to easily return to their favorite spots and activities, they can also be ambassadors as we welcome guests and visitors back to Chicago

For more information about Tourism & Hospitality Forward or to sign up, visit here.

What Others Are Saying About Tourism & Hospitality Forward

«We understand that re-opening businesses is not a one-size-fits-all approach. We will have to be strategic with gradually opening and monitoring cases at the same time, ensuring businesses adhere to all safety precautions according to City and State standards,» said Blanca Soto, Executive Director of Little Village Chamber of Commerce. «We and our members plan to partner with Tourism & Hospitality Forward, the City and the State to keep businesses constantly informed on the safest and most viable approaches to keep their workforce and our customers confident and safe.»

«The Illinois Hotel & Lodging Association has worked with our member companies in recent weeks to ensure that our team members and guests not only feel safe when they return to our hotels but are safe,» said Michael Jacobson, President and CEO of the Illinois Hotel & Lodging Association. «We have released specific guidance to hotels related to increased cleanliness and safety standards and continue to work with the City of Chicago and the State of Illinois to define what reopening our tourism economy will look like to help revitalize Chicago’s economy. For our members, the day cannot come soon enough to rehire their employees and welcome visitors into our hotels once again, but we must ensure that it is done in a safe way. We are taking the steps to ensure that we do just that.»

«I’m honored to have been appointed to Choose Chicago’s Board of Directors and to continue to partner with Mayor Lightfoot on broadening the impact and reach of Chicago’s cultural institutions. We look forward to reopening the Art Institute— and the City of Chicago— in a way that feels comfortable and safe for our staff and visitors from our community and around the world,» said James Rondeau, President, Art Institute of Chicago.

«I’m honored to have been appointed to Choose Chicago’s Board of Directors,» said Ayesha Jaco, Executive Director of West Side United. «Now more than ever our entire community needs to collaborate on, not only a safe and responsible way to reopen our businesses, but an inclusive way as all of Chicago faces this moment together.»

«The cornerstone of Chicago’s 77 communities, restaurants have been devastated by the COVID-19 crisis,» said Sam Toia, President and CEO, Illinois Restaurant Association. «By mid-April, 321,000 of the state’s 594,900 industry employees had been laid off or furloughed; fifty five percent of operators had temporarily closed their businesses; and sales were down 80 percent. But when we talk about reopening responsibly, restaurants have a distinct advantage. Our teams are already accustomed to operating at the highest of standards when it comes to sanitation. Managers, chefs, servers, and bartenders complete mandatory certification courses equipping them with knowledge and best practices designed to protect the well-being of their employees and guests on a daily basis. As we set our sights on reopening, our already health-focused industry has a strong foundation for implementing clear guidelines that will allow their businesses to safely resume dining room service while prioritizing public health.»

About Choose Chicago

Choose Chicago is the official sales and marketing organization responsible for promoting Chicago as a global visitor destination leveraging the city’s unmatched assets to ensure the economic vitality of the city and its member business community. For more information, visit choosechicago.com. Follow @ChooseChicago on Facebook, Instagram and Twitter.

Logo – https://mma.prnewswire.com/media/1171596/Choose_Chicago_Logo.jpg  

SOURCE Choose Chicago

Choose Chicago anuncia Tourism & Hospitality Forward para recibir nuevamente a los visitantes a Chicago de manera responsable

CHICAGO, 21 de mayo de 2020 /PRNewswire-HISPANIC PR WIRE/ — En la Asamblea Anual de Choose Chicago celebrada hoy, la organización anunció <a target="_blank"…

CHICAGO, 21 de mayo de 2020 /PRNewswire-HISPANIC PR WIRE/ — En la Asamblea Anual de Choose Chicago celebrada hoy, la organización anunció Tourism & Hospitality Forward, una nueva iniciativa destinada a acelerar y estimular la industria turística de Chicago después del coronavirus y ayudar a agilizar la recuperación económica de la ciudad. Hasta la fecha, una coalición integrada por más de 250 organizaciones y empresas locales relacionadas con el turismo, la hospitalidad, las reuniones y los eventos han firmado un compromiso de adhesión, colaboración y turismo y hospitalidad socialmente responsables, que inspirará confianza a los residentes y visitantes en su regreso a Chicago.

«La actual crisis ha sido sencillamente devastadora para muchos, incluso para la industria del turismo y la hospitalidad, y entendemos que estos desafíos sin precedentes requieren acciones rápidas y sin precedentes para restaurar este motor económico de la ciudad», dice Glenn Eden, presidente de la junta directiva de Choose Chicago. «Nuestra primera prioridad es la promoción de un turismo socialmente responsable. Demostraremos a nuestros visitantes que, con los cambios operativos y las precauciones adoptadas, es seguro volver a disfrutar de Chicago«.

Las industrias del turismo, la hospitalidad, las reuniones y los eventos de Chicago fueron algunos de los sectores más azotados por la pandemia del covid-19. Mientras la ciudad transita una reapertura gradual, esta alianza de socios industriales trabajará mancomunadamente para crear prácticas ideales y medidas para la salud y la seguridad de residentes y visitantes por igual cuando las instituciones culturales, los hoteles, las atracciones y los restaurantes retornen a sus negocios habituales y reciban a los visitantes.

«Aplaudo el compromiso de Choose Chicago de elaborar soluciones seguras y colaborativas para el profundo impacto que el covid-19 ha tenido en la vital industria del turismo y la hospitalidad de nuestra ciudad», declaró la alcaldesa Lori E. Lightfoot. «A pesar de los desafíos que enfrentamos, la fortaleza de nuestra recuperación se está construyendo sobre la base de asociaciones innovadoras como estas, de respaldo mutuo, que se apoyan en los datos de esta enfermedad y nos permiten construir y crecer más resilientes, inclusivos y poderosos que nunca».

El compromiso consta de cuatro componentes:

  • PLANIFICACIÓN SOCIALMENTE RESPONSABLE: Priorizaremos la seguridad de nuestros visitantes y empleados adhiriéndonos a directrices de salud pública y seremos líderes en el turismo y la hospitalidad socialmente responsables.
  • PARTICIPACIÓN DEDICADA Y ESTRATÉGICA: Reconoceremos la importancia de adoptar un enfoque estratégico y colaborativo dedicando tiempo a alinear a los sectores y desarrollar los planes graduales que necesitamos para prosperar en este entorno difícil.
  • EXCELENCIA AUTÉNTICA E INCLUSIVA: Trabajaremos mancomunadamente para estimular el tráfico de visitantes y huéspedes de Chicago aumentando nuestros esfuerzos para crear formas únicas de aprovechar todos los barrios dinámicos y los recursos auténticos de la ciudad.
  • PROMOCIÓN SIN PRECEDENTES DE CHICAGO: Abogaremos por todo lo que Chicago tiene para ofrecer mediante productos promocionales combinados y colaboración en ofertas compartidas para crear un entorno mutuamente beneficioso para la industria y, finalmente, una economía más fuerte para la ciudad.

Además, Tourism & Hospitality Forward anunció un marco de extensión y participación que los integrantes podrán aprovechar para atraer a los visitantes de regreso a Chicago cuando sea el momento. Este marco incluye:

  • Promoción de la reapertura de Chicago de una manera calibrada con programas y promociones, tales como «vacaciones en casa» (staycations), destinadas a atraer a públicos locales.
  • Lanzamiento de iniciativas estacionales para atraer turistas a Chicago con énfasis en los estados vecinos.
  • Fortalecimiento de la idea de que Chicago seguirá siendo el mejor lugar para hacer negocios mientras la ciudad compite por eventos y reuniones.
  • Optimización de todo lo que Chicago tiene para ofrecer mediante una campaña de marketing unificada.

La planificación ya ha comenzado con varios grupos de trabajo alineados por sector, entre ellos, alojamientos, museos y atracciones, arte y cultura, festivales y eventos especiales, incluso deportes y un enfoque especial en barrios únicos y diversos.

«Estos grupos empezaron a reunirse centrándose en estrategias de reapertura iniciales y casi inmediatas», dice Eden. «Pero fueron evolucionando y han pasado a apoyar y colaborar con la Fuerza de Trabajo de Reapertura y Recuperación de más largo plazo de la alcaldesa Lightfoot, incluido el marketing y el desarrollo económico de la ciudad en general».

«Los visitantes tradicionales y los delegados a convenciones serán nuestro objetivo final en el proceso de recuperación», dice David Whitaker, presidente y director ejecutivo de Choose Chicago. «En las etapas iniciales de la reapertura, tendremos que centrarnos en nuestros residentes locales y los visitantes de suburbios y regiones vecinas, y atenernos a ellos y a quienes puedan llegar en sus propios vehículos. Aunque ellos serán los primeros en regresar fácilmente a sus lugares y actividades favoritas, también podrán ser embajadores mientras recibimos a huéspedes y visitantes nuevamente en Chicago«.

Para más información acerca de Tourism & Hospitality Forward o para inscribirse, haga clic aquí.

Qué se está diciendo acerca de Tourism & Hospitality Forward

«Entendemos que la reapertura de los negocios no es algo que permita un abordaje igual para todos. Tendremos que adoptar un enfoque estratégico, con una apertura gradual y casos de monitoreo simultáneos, y asegurar que las empresas cumplan todas las precauciones de los estándares de seguridad de la ciudad y el estado», afirma Blanca Soto, directora ejecutiva de la Cámara de Comercio de Little Village. «Nosotros y nuestros miembros planeamos asociarnos con Tourism & Hospitality Forward, la ciudad y el estado para tener a las empresas constantemente informadas sobre los enfoques más seguros y viables para mantener a nuestra fuerza laboral y nuestros clientes confiados y seguros».

«La Illinois Hotel & Lodging Association ha trabajado con sus compañías miembros en las últimas semanas para asegurar que los integrantes de nuestros equipos y nuestros huéspedes no solo se sientan seguros cuando regresen a nuestros hoteles, sino que estén realmente seguros», comenta Michael Jacobson, presidente y director ejecutivo de la Illinois Hotel & Lodging Association. «Hemos publicado directrices específicas para los hoteles relacionadas con una mayor limpieza y estándares de seguridad, y seguiremos trabajando con la ciudad de Chicago y el estado de Illinois para definir cómo será la reapertura de nuestra economía turística para ayudar a revitalizar la economía de Chicago. Nuestros miembros están ansiosos por recontratar a sus empleados y volver a recibir visitantes en nuestros hoteles, pero debemos garantizar que se haga de manera segura. Estamos adoptando las medidas necesarias para asegurarnos de hacer exactamente eso».

«Es un honor para mí haber sido designado en la junta directiva de Choose Chicago y seguir colaborando con la alcaldesa Lightfoot para ampliar el impacto y el alcance de las instituciones culturales de Chicago. Ansiamos reabrir el Art Institute —y la ciudad de Chicago— de una forma confortable y segura para nuestro personal y para los visitantes de nuestra comunidad y de todo el mundo», dice James Rondeau, presidente del Art Institute de Chicago.

«Me siento honrada de haber sido designada en la junta directiva de Choose Chicago», dice Ayesha Jaco, directora ejecutiva de West Side United. «Hoy más que nunca, toda nuestra comunidad tiene que colaborar para reabrir nuestros negocios de una forma que no solo sea responsable y segura, sino también inclusiva, pues toda Chicago enfrenta este momento junta».

«Los restaurantes, piedra angular de las 77 comunidades de Chicago, han sido devastados por la crisis del covid-19″, dice Sam Toia, presidente y director ejecutivo de la Illinois Restaurant Association. «Para mediados de abril, 321,000 de los 594,900 empleados del sector en el estado habían sido despedidos o licenciados, el 55% de los operadores ya habían cerrado sus negocios temporalmente, y las ventas habían caído un 80%. Pero cuando hablamos de una reapertura responsable, los restaurantes tienen una ventaja distintiva. Nuestros equipos ya están acostumbrados a operar con los más altos estándares de sanidad. Gerentes, cocineros, camareros y cantineros realizan cursos de certificación obligatorios que los preparan con conocimientos y buenas prácticas diseñadas para proteger el bienestar de empleados y visitantes todos los días. Mientras ponemos la mirada en la reapertura, nuestra industria, ya enfocada en la salud, tiene bases sólidas para implementar directrices claras que permitirán a nuestros negocios reiniciar con seguridad los servicios de comedor, priorizando al mismo tiempo la salud pública».

Acerca de Choose Chicago

Choose Chicago es la organización oficial de ventas y marketing responsable de promover Chicago como destino global para visitantes, aprovechando los recursos incomparables de la ciudad para asegurar la vitalidad económica de la ciudad y de su comunidad de negocios miembros. Si desea más información, visite choosechicago.com. Siga a @ChooseChicago en Facebook, Instagram y Twitter.

Logo – https://mma.prnewswire.com/media/1171596/Choose_Chicago_Logo.jpg  

FUENTE Choose Chicago

Warner Music and Humanity Lab Foundation launch a new hit song and campaign in partnership with the United Nations in support of the UN Sustainable Development Goals

SAO PAULO, May 21, 2020 /PRNewswire-PRWeb/ — Global brands and international pop stars, Brazilian singer IZA and American singer Maejor, join to launch a global campaign aimed at mobilizing people around the world in support of the United Nations Sustainable Development Goals and to inspire a movement of social change and public good.

The online global launch (taking place at 1pm EST | 2pm Brazil) — organized by the Humanity Lab…

SAO PAULO, May 21, 2020 /PRNewswire-PRWeb/ — Global brands and international pop stars, Brazilian singer IZA and American singer Maejor, join to launch a global campaign aimed at mobilizing people around the world in support of the United Nations Sustainable Development Goals and to inspire a movement of social change and public good.

The online global launch (taking place at 1pm EST | 2pm Brazil) — organized by the Humanity Lab Foundation in partnership with Warner Music and in collaboration with the United Nations Brazil, UNESCO, United Nations Refugee Agency (UNHCR) Brazil, and the World YMCA– aims to be a powerful moment to galvanize conversations around the urgent action needed to solve complex social and political challenges.

Intended to build on the success of the ambitious 2030 Sustainable Development Agenda («Sustainable Development Goals»), which drew on the voices of millions of people prior to their adoption in 2015, Be The One leverages creative media partnerships, to make the Sustainable Development Goals more accessible, easy to understand, and relatable to people and organizations around the world.

The Be The One campaign launch will also serve as the global premiere of a new pop song, «Let Me Be The One», featuring award-winning international singers Iza and Maejor, that will serve as the theme song for the campaign.
«We believe that music has the power to unite, promote changes and touch people’s lives. For that reason, we are extremely happy with this partnership with the Humanity Lab Foundation, in support of the United Nations. We are proud to be part of this campaign and, also, contribute to the launch of the track ‘Let Me Be The One’. We trust that it will help spread this message of union and solidarity that we truly believe in and which the world needs the most in these difficult times. I’m grateful to IZA and Maejor for giving their voices to this cause,» said Sergio Affonso, president of Warner Music Brazil.

Through innovative programming, Be The One facilitates civic engagement and mobilizes action to solve complex global challenges, including equity, gender equality, ending poverty, ending conflict, promoting peace, climate action and human rights. Be The One unites people, businesses, governments, and civil society around a shared vision to achieve a better world, by providing the tools and community to unlock purpose and human capacity to create lasting change.

«Real change will come only from the participation and contribution of all: governments, companies, civil society organizations, and individuals,» said the Resident Coordinator of the United Nations in Brazil, Mr. Niky Fabiancic. «Especially now, in face of the Covid-19 crisis, it is clear that we will only be able to rebuild our lives if we cooperate, and by working together we can rebuild a better version of the world, with more unity among peoples, more equality and justice, better health and education systems, and more respect for the environment.»

Coinciding with the United Nations World Day for Cultural Diversity for Dialogue and Development, Be The One and Let Me Be The One aim to harness the power of music and art to inspire social change and connect people across languages, geographies, and cultures.

«Today, we celebrate the World Day for Cultural Diversity for Dialogue and Development during an unprecedented global pandemic. The current crisis must lead to new efforts to increase the resilience and sustainability of the cultural sector, while highlighting the importance of heritage, museums and creativity. Culture makes communities resilient. It contains a wealth of knowledge for addressing environmental challenges. It powers innovation, creativity and economic growth. It is a foundation for social cohesion and equity. Each of us has the power to create the future we want. Culture is the key to unlocking this better future, and this is what we celebrate and champion today,» said Mr. Ernesto Ottone Ramírez, Assistant Director-General for Culture of UNESCO, partners of the Be The One Campaign.

Conceived and curated by Hazami Barmada, Be The One is organized by the Humanity Lab Foundation. Since 2017, the Humanity Lab Foundation has hosted initiatives in partnership with the UN Office for Partnerships and the Office of the President of the 73rd United Nations General Assembly to amplify global engagement around the Sustainable Development Goals.

«In light of the current global discourse and crippling fear from the spread of COVID, Be The One launches to inspire a sense of hope, collective responsibility and conversation around creating the future we all want and desire– together,» said Hazami Barmada, Founder and Chief Executive Officer of the Humanity Lab Foundation. «»Hope» is not a strategy, the world needs more than hope. We are living in times of grave injustice, human rights violations, and a planet that is deeply impacted by climate change. At the Humanity Lab Foundation, we are committed to creating thought-leadership that challenges the systems that are not working and create programming to forge a new way forward based on equity, equality and empathetic leadership. We believe in the power of every-day people to be that change.»

As part of Be The One, the Humanity Lab Foundation will offer a Harvard-designed Adaptive Leadership and Change Management Masterclass to 100,000 individuals and organizations by May 2021. The online class will help business and civil society leaders navigate uncertainty and adapt to rapid needs in the development sector.

Year-round, Be The One will create educational and advocacy initiatives to build a localized movement around action. On-going engagements will be facilitated in collaboration with campaign partners and spearheaded by campaign brand ambassadors, IZA and Maejor.

Let Me Be The One official music video features a cast of diverse people with an aim of highlighting diversity and inclusion that is central to the campaign. With the support of the United Nations Refugee Agency in Brazil, cast members represent refugee, homeless, disability, LGBTQI+, elderly, indigenous, body-positive and international communities. Featured diversity includes cast from 14 countries including China, Palestine, Syria, Venezuela, Congo, and the Amazon.

Link to the Be The One Website: betheone.care

For further information on the campaign, please contact Hazami Barmada, CEO of Humanity Lab Foundation, hazami@humanitylabfoundation.org

For further information on the song, please contact Beatriz Von Zuben, Press Coordinator from Warner Music Brazil, beatriz.vonzuben@warnermusic.com

For further information on UN Brazil, please contact Isadora Ferreira, isadora.ferreira@un.org

 

SOURCE Humanity Lab Foundation

Abierta la convocatoria de nominaciones para la edición 2021 de los premios HITEC 100

CHICAGO, 21 de mayo de 2020 /PRNewswire-HISPANIC PR WIRE/ — HITEC, la principal organización de liderazgo ejecutivo global compuesta por altos ejecutivos de negocios y tecnología, está aceptando nominaciones para sus prestigiosos premios HITEC…

CHICAGO, 21 de mayo de 2020 /PRNewswire-HISPANIC PR WIRE/ — HITEC, la principal organización de liderazgo ejecutivo global compuesta por altos ejecutivos de negocios y tecnología, está aceptando nominaciones para sus prestigiosos premios HITEC 100 hasta el 19 de julio de 2020.

¡Presente sus nominaciones hoy mismo! Haga clic aquí para consultar los criterios para la nominación y el formulario para proponer a sus nominados.

Desde 2008, HITEC ha compilado una lista anual que reconoce las aportaciones y los logros de los 100 ejecutivos y empresarios hispanos más influyentes y destacados en el sector tecnológico. La misión de los premios HITEC 100 es homenajear a ejecutivos sobresalientes que se destacan en la industria de la tecnología, inspiran a la juventud a desarrollar una trayectoria en el campo de la tecnología y motivan a los profesionales para que sigan mejorando y vinculándose con comunidades hispanas de todo el mundo.

Conozca a los ganadores anteriores de los premios HITEC 100: Clase de 2020 de ganadores de los premios HITEC 100 

Acerca de HITEC:
Fundada para aumentar la representación hispana en la industria de la tecnología que tiene poca diversidad, HITEC es una organización de liderazgo ejecutivo global de primer nivel compuesta por altos ejecutivos de negocios y tecnología que han desarrollado carreras sobresalientes en el campo de la tecnología. La red principal de HITEC se extiende por todo el continente americano y se centra en la formación de líderes ejecutivos y tecnológicos, equipos de liderazgo, corporaciones y modelos de referencia más sólidos en un mundo rápidamente cambiante, más horizontal y más centrado en la tecnología. Estos líderes globales incluyen ejecutivos que dirigen empresas incluidas en la lista Global 1000, mientras que otros dirigen algunas de las mayores empresas de tecnología propiedad de hispanos en toda las Américas. HITEC fomenta el crecimiento empresarial y profesional de sus miembros y abastece la reserva de ejecutivos con la próxima generación de líderes tecnológicos hispanos.

 

FUENTE Hispanic Information Technology Executive Council

The doctor reminds Reggae fans to live their lives

SPRING HILL, Fla., May 21, 2020 /PRNewswire-PRWeb/ — The doctor’s order is pretty plain and simple, «Live your life»; that’s the name of the new song from Dancehall / Reggae artist, Doctor Serious and that’s what he wants reggae fans to do.

The song was made to create a party vibes and is featured on a beat that is a mashup of Reggae, Dancehall, Soca, Afro beat and Reggaeton.

«I just wanted to make a song that could put people in a happy vibes and get them dancing,» Doctor Serious…

SPRING HILL, Fla., May 21, 2020 /PRNewswire-PRWeb/ — The doctor’s order is pretty plain and simple, «Live your life»; that’s the name of the new song from Dancehall / Reggae artist, Doctor Serious and that’s what he wants reggae fans to do.

The song was made to create a party vibes and is featured on a beat that is a mashup of Reggae, Dancehall, Soca, Afro beat and Reggaeton.

«I just wanted to make a song that could put people in a happy vibes and get them dancing,» Doctor Serious said.

While the intention of the song is to get people on the dancefloor, it is also packed with some deep thing lyrics.

«Tomorrow is not guaranteed / the stars and the Galaxy / live your life» is just one of the powerful lines from the song that will have the listener in deep meditation, especially during these uncertain times.

The song is now available on iTunes, Apple music, Spotify, Amazon and all other popular music platforms.

Born in Jamaica, Dr. Serious migrated to New York City during his teenage years where he mastered his skill has a deejay on the Brooklyn sound systems.

«I even had my own sound system called Golden Child which my dad built for me after he saw my passion for the music,» he said.

For booking or more information
Phone: 352-515-0953
Instagram @dr.serious876

 

SOURCE Dr. Serious

2021 HITEC 100 – Now Accepting Nominations

CHICAGO, May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — HITEC, the premier global executive leadership organization of senior-level business and technology executives, is accepting nominations for its prestigious HITEC 100 Awards until July 19, 2020.

Nominate today! <a target="_blank"…

CHICAGO, May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — HITEC, the premier global executive leadership organization of senior-level business and technology executives, is accepting nominations for its prestigious HITEC 100 Awards until July 19, 2020.

Nominate today! Click here to view the HITEC 100 nomination criteria and nomination form.

Since 2008, HITEC has compiled an annual list recognizing the contributions and accomplishments of the 100 most influential and notable Hispanic executives and entrepreneurs in the technology industry. The mission of the HITEC 100 is to recognize outstanding executives who excel in the business of technology, inspire young people to pursue careers in technology and motivate professionals to continue to excel and connect with Hispanic communities across the globe.

View Past HITEC 100 Award Winners: Class of 2020 HITEC 100 Award Winners

About HITEC:
Founded to increase Hispanic representation in the diversity-challenged technology industry, HITEC is a premier global executive leadership organization of senior business and technology executives who have built outstanding careers in technology. HITEC’s premiere network spans the Americas and is focused on building stronger technology and executive leaders, leadership teams, corporations, and role models in a rapidly changing, flatter, and technology centric world. These global leaders include executives leading Global 1000 corporations while others lead some of the largest Hispanic-owned technology firms across the Americas. HITEC enables business and professional growth for its members and fills the executive pipeline with the next generation of Hispanic technology leaders.

SOURCE Hispanic Information Technology Executive Council

2021 HITEC 100 – Now Accepting Nominations

CHICAGO, May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — HITEC, the premier global executive leadership organization of senior-level business and technology executives, is accepting nominations for its prestigious HITEC 100 Awards until July 19, 2020.

Nominate today! <a target="_blank"…

CHICAGO, May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — HITEC, the premier global executive leadership organization of senior-level business and technology executives, is accepting nominations for its prestigious HITEC 100 Awards until July 19, 2020.

Nominate today! Click here to view the HITEC 100 nomination criteria and nomination form.

Since 2008, HITEC has compiled an annual list recognizing the contributions and accomplishments of the 100 most influential and notable Hispanic executives and entrepreneurs in the technology industry. The mission of the HITEC 100 is to recognize outstanding executives who excel in the business of technology, inspire young people to pursue careers in technology and motivate professionals to continue to excel and connect with Hispanic communities across the globe.

View Past HITEC 100 Award Winners: Class of 2020 HITEC 100 Award Winners

About HITEC:
Founded to increase Hispanic representation in the diversity-challenged technology industry, HITEC is a premier global executive leadership organization of senior business and technology executives who have built outstanding careers in technology. HITEC’s premiere network spans the Americas and is focused on building stronger technology and executive leaders, leadership teams, corporations, and role models in a rapidly changing, flatter, and technology centric world. These global leaders include executives leading Global 1000 corporations while others lead some of the largest Hispanic-owned technology firms across the Americas. HITEC enables business and professional growth for its members and fills the executive pipeline with the next generation of Hispanic technology leaders.

SOURCE Hispanic Information Technology Executive Council

A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19 Patients: Montefiore-Einstein Scientists Lead Two Trials of Leronlimab

BRONX, N.Y., May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the «cytokine storm» that inflames and fatally damages the lungs and other…

BRONX, N.Y., May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the «cytokine storm» that inflames and fatally damages the lungs and other organs of many COVID-19 patients.

Montefiore

Harish Seethamraju, M.D., an organ transplant specialist and a member of the department of medicine at Montefiore and Einstein, researched leronlimab early in the pandemic, and realized its potential for treating his transplant patients who had COVID-19. He then obtained «compassionate use» permission from the Food and Drug Administration so that he and his colleagues could use leronlimab on 10 severely ill COVID-19 patients, six of them transplant patients from various organ transplant programs.

«By calming the overactive immune systems of these patients, leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients,» said Dr. Seethamraju. All 10 patients had extremely high blood levels of CCL5, which are inflammatory molecules known as cytokines. This is why the extreme inflammatory response is known as the «cytokine storm.» Leronlimab interfered with those CCL5 molecules, preventing them from directing immune cells to swarm into and inflame the lungs and other organs. 

On May 5th, a study describing promising results for those 10 severely ill patients was made public on the website, MedRxiv, a resource especially useful during the COVID-19 pandemic to make research quickly available to the scientific community. Co-authored by Dr. Seethamraju, the study reported that five of the 10 patients treated with leronlimab survived; the study also described the drug as «a novel approach» to resolving unchecked inflammation.   

Based on the positive results with those patients, the FDA approved Dr. Seethamraju’s application for a phase 2 trial of leronlimab. That trial began enrolling both inpatients and outpatients with mild-to-moderate COVID-19 on April 2. A total of 75 will participate.

«Such patients all too often seem to be recovering, but then crash and burn when their lungs are overwhelmed by an inflammatory reaction that makes breathing impossible, «says Dr. Seethamraju. «The FDA is concerned that there is no treatment for those people.»

Patients in the multicenter trial receive two injections, one week apart, of either leronlimab or a placebo and are assessed periodically over six weeks for fever, muscle pain, difficulty breathing and cough. Dr. Seethamraju is a co-principal investigator of the Montefiore trial site, along with Scott A. Scheinin, M.D., surgical director of advanced pulmonary failure and lung transplantation, division chief of thoracic surgery and surgical oncology, and director of the Bloodless Heart Surgical Program at Montefiore.

On April 16th, Montefiore enrolled the first patient in a second FDA-approved leronlimab clinical trial: a randomized, double blind trial to assess the optimal dose, safety and effectiveness of leronlimab in treating severely ill COVID-19 patients. The 390 patients taking part in this multicenter trial will receive two weekly doses of either leronlimab or a placebo; there will be twice as many patients receiving leronlimab as those receiving the placebo. The trial will evaluate the patients’ survival at 14- and 28-days following treatment.

The two leronlimab clinical trials are being conducted under the direction of the departments of cardiothoracic surgery and medicine at Montefiore and Einstein. Leronlimab is a monoclonal antibody drug developed by CytoDyn Inc., a biotechnology company based in Vancouver, WA.

About Montefiore Health System Montefiore Health System is one of New York’s premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children’s Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.

Logo – https://mma.prnewswire.com/media/675671/Montefiore_Logo.jpg

SOURCE Montefiore Health System; Albert Einstein College of Medicine

A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19 Patients: Montefiore-Einstein Scientists Lead Two Trials of Leronlimab

BRONX, N.Y., May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the «cytokine storm» that inflames and fatally damages the lungs and other…

BRONX, N.Y., May 21, 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab may prevent the «cytokine storm» that inflames and fatally damages the lungs and other organs of many COVID-19 patients.

Montefiore

Harish Seethamraju, M.D., an organ transplant specialist and a member of the department of medicine at Montefiore and Einstein, researched leronlimab early in the pandemic, and realized its potential for treating his transplant patients who had COVID-19. He then obtained «compassionate use» permission from the Food and Drug Administration so that he and his colleagues could use leronlimab on 10 severely ill COVID-19 patients, six of them transplant patients from various organ transplant programs.

«By calming the overactive immune systems of these patients, leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients,» said Dr. Seethamraju. All 10 patients had extremely high blood levels of CCL5, which are inflammatory molecules known as cytokines. This is why the extreme inflammatory response is known as the «cytokine storm.» Leronlimab interfered with those CCL5 molecules, preventing them from directing immune cells to swarm into and inflame the lungs and other organs. 

On May 5th, a study describing promising results for those 10 severely ill patients was made public on the website, MedRxiv, a resource especially useful during the COVID-19 pandemic to make research quickly available to the scientific community. Co-authored by Dr. Seethamraju, the study reported that five of the 10 patients treated with leronlimab survived; the study also described the drug as «a novel approach» to resolving unchecked inflammation.   

Based on the positive results with those patients, the FDA approved Dr. Seethamraju’s application for a phase 2 trial of leronlimab. That trial began enrolling both inpatients and outpatients with mild-to-moderate COVID-19 on April 2. A total of 75 will participate.

«Such patients all too often seem to be recovering, but then crash and burn when their lungs are overwhelmed by an inflammatory reaction that makes breathing impossible, «says Dr. Seethamraju. «The FDA is concerned that there is no treatment for those people.»

Patients in the multicenter trial receive two injections, one week apart, of either leronlimab or a placebo and are assessed periodically over six weeks for fever, muscle pain, difficulty breathing and cough. Dr. Seethamraju is a co-principal investigator of the Montefiore trial site, along with Scott A. Scheinin, M.D., surgical director of advanced pulmonary failure and lung transplantation, division chief of thoracic surgery and surgical oncology, and director of the Bloodless Heart Surgical Program at Montefiore.

On April 16th, Montefiore enrolled the first patient in a second FDA-approved leronlimab clinical trial: a randomized, double blind trial to assess the optimal dose, safety and effectiveness of leronlimab in treating severely ill COVID-19 patients. The 390 patients taking part in this multicenter trial will receive two weekly doses of either leronlimab or a placebo; there will be twice as many patients receiving leronlimab as those receiving the placebo. The trial will evaluate the patients’ survival at 14- and 28-days following treatment.

The two leronlimab clinical trials are being conducted under the direction of the departments of cardiothoracic surgery and medicine at Montefiore and Einstein. Leronlimab is a monoclonal antibody drug developed by CytoDyn Inc., a biotechnology company based in Vancouver, WA.

About Montefiore Health System Montefiore Health System is one of New York’s premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children’s Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.

Logo – https://mma.prnewswire.com/media/675671/Montefiore_Logo.jpg

SOURCE Montefiore Health System; Albert Einstein College of Medicine

Prometedor Fármaco para el Tratamiento de la Inflamación Pulmonar Severa en Pacientes de COVID-19: Científicos de Montefiore-Einstein Lideran Dos Ensayos Con Leronlimab

BRONX, N.Y., 21 Mayo de 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System y el Albert Einstein College of Medicine son las primeras instituciones de la nación en empezar a evaluar un medicamento en proceso de investigación en dos ensayos clínicos aprobados por el FDA: el primero de ellos tenía como objetivo tratar casos de COVID-19 de moderados a leves, y el segundo tratar casos severos de esta enfermedad. Los científicos tienen esperanzas de que el medicamento leronlimab pueda…

BRONX, N.Y., 21 Mayo de 2020 /PRNewswire-HISPANIC PR WIRE/ — Montefiore Health System y el Albert Einstein College of Medicine son las primeras instituciones de la nación en empezar a evaluar un medicamento en proceso de investigación en dos ensayos clínicos aprobados por el FDA: el primero de ellos tenía como objetivo tratar casos de COVID-19 de moderados a leves, y el segundo tratar casos severos de esta enfermedad. Los científicos tienen esperanzas de que el medicamento leronlimab pueda prevenir la llamada «tormenta de citoquinas», una reacción del organismo que inflama y daña los pulmones y otros órganos de muchos pacientes de COVID-19.

Montefiore

El Dr. Harish Seethamraju, un especialista en transplante de órganos y miembro del departamento de medicina de Montefiore y Einstein, investigó con este medicamento en los inicios de la pandemia y se dio cuenta del potencial que tenía para tratar a sus pacientes de trasplantes que habían tenido COVID-19. Luego obtuvo del Food and Drug Administrartion (la máxima autoridad farmacológica del país) un permiso especial de «aplicación compasiva» para administrar leronlimab a 10 pacientes de COVID-19 en estado extremadamente grave, seis de los cuales eran, además, pacientes de diversos tipos de transplante. 

«El leronlimab calmó el sistema inmunitario hiperactivo de estos pacientes y, al hacerlo, detuvo la inflamación y la coagulación sanguínea que tanto daño causan a los pulmones, el hígado y los riñones de los pacientes más graves de COVID-19», dijo el Dr. Seethamraju. Los 10 pacientes tenían niveles extremadamente altos de CCL5, unas moléculas inflamatorias conocidas como citoquinas. Y son ellas las responsables de las llamadas «tormentas de citoquinas». El leronlimab interfirió con estas moléculas CCL5, y evitó que dieran a las células inmunes la orden de atacar masivamente e inflamar los pulmones y otros órganos. 

El pasado 5 de mayo los prometedores resultados sobre el estudio en 10 pacientes gravemente enfermos se hizo público en el sitio web, MedRxiv: una fuente especialmente útil durante la pandemia de COVID-19 cuyo fin es que las investigaciones estén disponibles para la comunidad científica de la manera más rápida posible. El estudio, codirigido por el Dr. Seethamraju, informó que cinco de los 10 pacientes tratados con leronlimbad sobrevivieron; el estudio también definió este fármaco como un «enfoque novedoso» para resolver inflamaciones dadas por imposibles.  

A partir de estos resultados positivos, el FDA aprobó la aplicación de una fase 2 en el ensayo clínico de leronlimab. El pasado 2 de abril el ensayo empezó a incorporar a pacientes internos y externos con COVID-19 de sintomatología leve a moderada. Un total de 75 pacientes participarán en él.

«Son muchas las veces que vemos a pacientes que parecen empezar a recuperarse y de pronto entran en barrena y se estrellan al producirse una reacción inflamatoria que imposibilita la respiración», dice el Dr. Seethamraju. «Y a la FDA le preocupa que no haya tratamiento para esas personas».

Los pacientes del ensayo multicéntrico reciben dos inyecciones con una semana de diferencia: una de ellas es leronlimab y la otra un placebo; los participantes son evaluados periódicamente durante seis semanas para detectar fiebre, dolores musculares, dificultades respiratorias y tos. El Dr. Seethamraju es co-investigador principal del ensayo de Montefiore, junto con el doctor Scott A. Scheinin, MD, Director Quirúrgico de Insuficiencia Pulmonar Avanzada y de Trasplante de Pulmón; así como  Jefe de División de Cirugía Torácica y Oncología Quirúrgica, y Director del Programa de Cirugía Cardíaca sin Sangre en Montefiore.

El 16 de abril, Montefiore inscribió al primer paciente en el segundo ensayo clínico de leronlimab aprobado por la FDA: un ensayo aleatorizado, doble ciego para evaluar la dosis óptima, la seguridad y la eficacia del leronlimab en el tratamiento de pacientes con COVID-19 gravemente enfermos. Los 390 pacientes que participan en este ensayo multicéntrico recibirán dos dosis semanales de leronlimab o un placebo; el número de pacientes que reciban leronlimab será el doble de los que recibirán el placebo. En este ensayo se evaluará la tasa de supervivencia de los pacientes a los 14 y a los 28 días del tratamiento.

Los dos ensayos clínicos de leronlimab se realizan bajo la dirección de los Departamentos de Cirugía y Medicina Cardiotorácica en Montefiore y Einstein. Leronlimab es un fármaco de anticuerpos monoclonales desarrollado por CytoDyn Inc., una compañía de biotecnología con sede en Vancouver, WA.

Sobre el Montefiore Health System El Montefiore Health System es una de las principales redes de salud académicas de Nueva York y es un líder reconocido en la prestación de atención médica personalizada de calidad excepcional; esta red es responsable de aproximadamente tres millones de personas en comunidades del Bronx, Westchester y Hudson Valley. Consta de 11 hospitales, incluido el Children’s Hospital at Montefiore, el Burke Rehabilitation Hospital y más de 200 centros de atención ambulatoria. La investigación clínica y traslacional avanzada de su escuela de medicina, el Albert Einstein College of Medicine, recae directamente en la atención al paciente y mejora los resultados. Desde los Centros de Excelencia Montefiore-Einstein en cáncer, cardiología y cuidados vasculares, pediatría y trasplantes, hasta su destacado programa de salud escolar, Montefiore es un sistema de atención médica totalmente integrado que da servicios médicos integrales y coordinados tanto a los pacientes como a sus familias. Más información en www.montefiore.org. Síganos en Twitter y visítenos en Facebook y YouTube.

Logo – https://mma.prnewswire.com/media/675671/Montefiore_Logo.jpg

FUENTE Montefiore Health System; Albert Einstein College of Medicine